KKR has agreed to acquire life sciences measurement and testing company LGC from Bridgepoint. Rumors during the auction process indicated the purchase price could be around £650 million. Operating in 22 countries, LGC focuses on the manufacture and distribution of reference materials, proprietary genomic products, and the provision of analytical and genomics testing services. Bridgepoint had acquired the company for €283 million in 2010. KKR is investing primarily through KKR European Fund IV.